Baisong Mei

Project head
Sanofi, Cambridge, MA, USA

Presentation(s):

• LB 01.1 - A Phase 3 study (ATLAS-PPX) to evaluate efficacy and safety of fitusiran, an siRNA therapeutic, in people with haemophilia A or B who have switched from prior factor or bypassing agent prophylaxis

  Sunday, July 10, 2022
  2:45 PM – 3:00 PM

• OC 50.2 - Fitusiran, an Investigational siRNA Therapeutic Targeting Antithrombin: Analysis of Antithrombin Levels and Thrombin Generation from a Phase 3 Study in People with Hemophilia A or B Without inhibitors

  Tuesday, July 12, 2022
  11:00 AM – 11:15 AM

• PB1152 - Fitusiran, an Investigational siRNA Therapeutic Targeting Antithrombin: Analysis of Antithrombin Levels and Thrombin Generation from a Phase 3 Study in People with Hemophilia A or B With Inhibitors

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM